On June 9th, PolyPid Ltd.* announced landmark topline results from its pivotal SHIELD II Phase 3 trial, demonstrating that D-PLEX100 achieved statistically significant reductions across all primary and secondary endpoints in preventing surgical site infections (SSIs). The study's compelling efficacy profile—including a 58% reduction in SSIs, 38% reduction in the composite primary endpoint, and 62% reduction in severe wound infections—validates the company's innovative PLEX technology platform and positions ...

On June 9th, PolyPid Ltd.* announced landmark topline results from its pivotal SHIELD II Phase 3 trial, demonstrating that D-PLEX100 achieved statistically significant reductions across all primary and secondary endpoints in preventing surgical site infections (SSIs). The study's compelling efficacy profile—including a 58% reduction in SSIs, 38% reduction in the composite primary endpoint, and 62% reduction in severe wound infections—validates the company's innovative PLEX technology platform and positions ...

Company Overview - PolyPid Ltd. is a late-stage biopharma company focused on improving surgical outcomes through innovative therapeutics [4] - The company utilizes its proprietary PLEX technology for controlled, prolonged-release of drugs, enabling precise delivery over several days to months [4] - PolyPid's lead product candidate, D-PLEX100, is currently in Phase 3 clinical trials aimed at preventing abdominal colorectal surgical site infections [4] Upcoming Events - PolyPid will participate in the Lytham Partners Spring 2025 Investor Conference, with a webcast presentation scheduled for May 29, 2025, at 10:15 a.m. ET [2] - The webcast will be accessible via the conference homepage and will be available for replay after the event [2] - Management will also engage in virtual one-on-one meetings with investors during the conference [3]